Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: An isobolographic analysis

European Journal of Pain

Volumn 13, Issue 7, 2009, Pages 665-672

  Luszczki, Jarogniew J ^a,b   Kolacz, Agnieszka ^a   Czuczwar, Miroslaw ^a   Przesmycki, Krzysztof ^a   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Drug interaction; Formalin test; Gabapentin; Isobolographic analysis; Tiagabine

Indexed keywords

FORMALDEHYDE; GABAPENTIN; TIAGABINE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHRONIC PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE; DRUG POTENTIATION; EXPERIMENTAL MODEL; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMINES; ANALGESICS; ANIMALS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FORMALDEHYDE; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; NIPECOTIC ACIDS; PAIN MEASUREMENT; PSYCHOMOTOR PERFORMANCE;

EID: 67649227514     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2008.08.002     Document Type: Article

References (69)

1. Andersen K.E., Braestrup C., Gronwald F.C., Jorgensen A.S., Nielsen E.B., Sonnewald U., et al. The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. J Med Chem 36 (1993) 1716-1725
2. Backonja M., Beydoun A., Edwards K.R., Schwartz S.L., Fonseca V., Hes M., et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280 (1998) 1831-1836
3. Berenbaum MC. What is synergy? Pharmacol Rev 1989;41:93-141 [Berenbaum MC. Erratum in: Pharmacol Rev 1989;41:422].
4. Bertrand S., Ng G.Y., Purisai M.G., Wolfe S.E., Severidt M.W., Nouel D., et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J Pharmacol Exp Ther 298 (2001) 15-24
5. Boissier J.R., Tardy J., and Diverres J.C. Une nouvelle méthode simple pour explorer l'action tranquilisante: le test de la cheminée. Med Exp (Basel) 3 (1960) 81-84
6. Caraceni A., Zecca E., Bonezzi C., Arcuri E., Yaya Tur R., Maltoni M., et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22 (2004) 2909-2917
7. Chapman V., Suzuki R., Chamarette H.L., Rygh L.J., and Dickenson A.H. Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 75 (1998) 261-272
8. Chen S.R., and Pan H.L. Effect of systemic and intrathecal gabapentin on allodynia in a new rat model of postherpetic neuralgia. Brain Res 1042 (2005) 108-113
9. Cheng J.K., Pan H.L., and Eisenach J.C. Antiallodynic effect of intrathecal gabapentin and its interaction with clonidine in a rat model of postoperative pain. Anesthesiology 92 (2000) 1126-1131
10. Codd E.E., Martinez R.P., Molino L., Rogers K.E., Stone D.J., and Tallarida R.J. Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain 134 (2008) 254-262
11. Czuczwar M., Kis J., Luszczki J., Turski W.A., and Przesmycki K. Evaluation of interaction between gabapentin and baclofen in the formalin test in mice. Pol J Pharmacol 55 (2003) 803-806
12. Dallel R., Raboisson P., Clavelou P., Saade M., and Woda A. Evidence for a peripheral origin of the tonic nociceptive response to subcutaneous formalin. Pain 61 (1995) 11-16
13. Deckers C.L., Czuczwar S.J., Hekster Y.A., Keyser A., Kubova H., Meinardi H., et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 41 (2000) 1364-1374
14. Di Trapani G., Mei D., Marra C., Mazza S., and Capuano A. Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ther 151 (2000) 145-148
15. Donovan-Rodriguez T., Dickenson A.H., and Urch C.E. Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 102 (2005) 132-140
16. Elia N., Lysakowski C., and Tramer M.R. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology 103 (2005) 1296-1304
17. Field M.J., Oles R.J., Lewis A.S., McCleary S., Hughes J., and Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 121 (1997) 1513-1522
18. Fink K., Dooley D.J., Meder W.P., Suman-Chauhan N., Duffy S., Clusmann H., et al. Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42 (2002) 229-236
19. Garry E.M., Delaney A., Anderson H.A., Sirinathsinghji E.C., Clapp R.H., Martin W.J., et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 18 (2005) 97-111
20. Gee N.S., Brown J.P., Dissanayake V.U., Offord J., Thurlow R., and Woodruff G.N. The novel anticonvulsant drug, gabapentin (neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271 (1996) 5768-5776
21. Grabovsky Y., and Tallarida R.J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J Pharmacol Exp Ther 310 (2004) 981-986
22. Greco W.R., Bravo G., and Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47 (1995) 331-385
23. Hunter J.C., Gogas K.R., Hedley L.R., Jacobson L.O., Kassotakis L., Thompson J., et al. The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 324 (1997) 153-160
24. Ipponi A., Lamberti C., Medica A., Bartolini A., and Malmberg-Aiello P. Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. Eur J Pharmacol 368 (1999) 205-211
25. Jin F., and Chung F. Multimodal analgesia for postoperative pain control. J Clin Anesth 13 (2001) 524-539
26. Jonker D.M., Voskuyl R.A., and Danhof M. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?. Epilepsia 48 (2007) 412-434
27. Kast R.E. Tiagabine may reduce bruxism and associated temporomandibular joint pain. Anesth Prog 52 (2005) 102-104
28. Laughlin T.M., Tram K.V., Wilcox G.L., and Birnbaum A.K. Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther 302 (2002) 1168-1175
29. Litchfield J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96 (1949) 99-113
30. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3 (1953) 285-290
31. Luszczki J.J. Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non parallel dose-response relationship curves. N-S Arch Pharmacol (2008) 10.1007/s00210-008-0305-8
32. Luszczki J.J. Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. N-S Arch Pharmacol 375 (2007) 105-114
33. Luszczki J.J., and Czuczwar S.J. Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis. N-S Arch Pharmacol 374 (2006) 51-64
34. Luszczki J.J., and Czuczwar S.J. Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. N-S Arch Pharmacol 369 (2004) 434-446
35. Luszczki J.J., Czuczwar M., Kis J., Krysa J., Pasztelan I., Swiader M., et al. Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice. An isobolographic analysis. Epilepsia 44 (2003) 1003-1013
36. Luszczki J.J., Ratnaraj N., Patsalos P.N., and Czuczwar S.J. Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. N-S Arch Pharmacol 373 (2006) 169-181
37. Luszczki J.J., Swiader M., Parada-Turska J., and Czuczwar S.J. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 28 (2003) 1817-1830
38. McCall W.D., Tanner K.D., and Levine J.D. Formalin induces biphasic activity in C-fibers in the rat. Neurosci Lett 208 (1996) 45-48
39. Meldrum B.S., and Chapman A.G. Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 40 Suppl. 9 (1999) S2-S6
40. Mellick G.A., and Mellick L.B. Reflex sympathetic dystrophy treated with gabapentin. Arch Phys Med Rehabil 78 (1997) 98-105
41. Ng G.Y., Bertrand S., Sullivan R., Ethier N., Wang J., Yergey J., et al. Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol 59 (2001) 144-152
42. Nielsen E.B., Suzdak P.D., Andersen K.E., Knutsen L.J., Sonnewald U., and Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 196 (1991) 257-266
43. Novak V., Kanard R., Kissel J.T., and Mendell J.R. Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res 11 (2001) 357-361
44. Ortiz M.I., Medina-Tato D.A., Sarmiento-Heredia D., Palma-Martínez J., and Granados-Soto V. Possible activation of the NO-cyclic GMP-protein kinase G-K+ channels pathway by gabapentin on the formalin test. Pharmacol Biochem Behav 83 (2006) 420-427
45. Pan H.L., Eisenach J.C., and Chen S.R. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther 288 (1999) 1026-1030
46. Patel M.K., Gonzalez M.I., Bramwell S., Pinnock R.D., and Lee K. Gabapentin inhibits excitatory synaptic transmission in the hyperalgesic spinal cord. Br J Pharmacol 130 (2000) 1731-1734
47. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl. 162 (1995) 31-34
48. Rosland J.H., Tjolsen A., Maehle B., and Hole K. The formalin test in mice. Effect of formalin concentration. Pain 42 (1990) 235-242
49. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
50. Shannon H.E., Eberle E.L., and Peters S.C. Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology 48 (2005) 1012-1020
51. Shimoyama M., Shimoyama N., and Hori Y. Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85 (2000) 405-414
52. Singh L., Field M.J., Ferris P., Hunter J.C., Oles R.J., Williams R.G., et al. The antiepileptic agent gabapentin (neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by d-serine. Psychopharmacology (Berlin) 127 (1996) 1-9
53. Sist T.C., Filadora V.A., Miner M., and Lema M. Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg Anesth 22 (1997) 473-478
54. Solaro C., and Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 75 (2004) 341
55. Stephen L.J., and Brodie M.J. Seizure freedom with more than one antiepileptic drug. Seizure 11 (2002) 349-351
56. Su T.Z., Lunney E., Campbell G., and Oxender D.L. Transport of gabapentin, a gamma-amino acid drug, by system l alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem 64 (1995) 2125-2131
57. Sufka K.J., Watson G.S., Nothdurft R.E., and Mogil J.S. Scoring the mouse formalin test: validation study. Eur J Pain 2 (1998) 351-358
58. h in rat CA1 pyramidal cells. Epilepsia 44 (2003) 150-156
59. Suzdak P.D., and Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36 (1995) 612-626
60. Swedberg M.D. The mouse grid-shock analgesia test: pharmacological characterization of latency to vocalization threshold as an index of antinociception. J Pharmacol Exp Ther 269 (1994) 1021-1028
61. Tallarida R.J. Drug synergism and dose-effect data analysis (2000), Chapman & Hall/CRC, Boca Raton, FL
62. Tallarida R.J. An overview of drug combination analysis with isobolograms. J Pharmacol Exp Ther 319 (2006) 1-7
63. Tallarida R.J. Interactions between drugs and occupied receptors. Pharmacol Ther 113 (2007) 197-209
64. Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 29 (1998) 233-249
65. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., and Hole K. The formalin test: an evaluation of the method. Pain 51 (1992) 5-17
66. Todorov A.A., Kolchev C.B., and Todorov A.B. Tiagabine and gabapentin for the management of chronic pain. Clin J Pain 21 (2005) 358-361
67. Towers S., Princivalle A., Billinton A., Edmunds M., Bettler B., Urban L., et al. GABAB receptor protein and mRNA distribution in rat spinal cord and dorsal root ganglia. Eur J Neurosci 12 (2000) 3201-3210
68. Yoon M.H., Choi J.I., and Jeong S.W. Spinal gabapentin and antinociception: mechanisms of action. J Korean Med Sci 18 (2003) 255-261
69. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 (1983) 109-110